Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2003

01-03-2003 | Original Paper

Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line

Authors: Albert A. Geldof, Marian A.B.D. Plaizier, Ilse Duivenvoorden, Marieke Ringelberg, Richard T. Versteegh, Don W.W. Newling, Gerrit J.J. Teule

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2003

Login to get access

Abstract

Purpose

To test the hypothesis that radiation-induced, transient G2/M arrest could potentially sensitize tumor cells to a subsequent, well-timed radiation dose.

Methods

PC-3 human prostate cancer cells were treated using either radiotherapy or 186Re-labeled hydroxyethylidene diphosphonate (186Re-HEDP) treatment in different combinations. The resulting cell cycle shift and clonogenic cell death were analyzed by DNA flow cytometry and colony forming cell assay, respectively.

Results

Radiation doses of 4 Gy and 8 Gy induced a transient G2/M arrest, with a maximum after approximately 16 h. The presence of 2 mM pentoxifylline effectively abrogated this radiation-induced G2 M arrest, confirming a cell-cycle checkpoint-mediated effect. A second dose of 4 Gy, timed at the height of the G2/M arrest, significantly increased clonogenic cell-kill compared to delivery after a suboptimal interval (10 h, 20 h or 25 h after the first radiation fraction). Moreover, timed second doses of 2 Gy, 3 Gy or 4 Gy yielded improved normalized treatment effects compared to non-pretreated control. Radionuclide treatment of PC-3 cells, using 186Re-HEDP (0.74 MBq/ml and 1.48 MBq/ml; total dose: 4.1 and 8.2 Gy, respectively) also induced a dose-dependent G2/M accumulation, which sensitized the cells to a subsequent external radiation dose of 2 Gy or 4 Gy. The observed pattern of cell-cycle shift towards a predominance of the G2/M phase is in line with the lack of functional p53 in this cell line.

Conclusions

Radiation-induced cell-cycle shift was shown to effectively confer increased radiosensitivity to prostate tumor cells. Optimally timed combination of radiotherapy and radionuclide therapy could thus significantly increase treatment efficacy.
Literature
go back to reference Bedford JS, Mitchell JB, Fox M (1980) Variations in responses of several mammalian cell lines to low dose-rate irradiation. In: Meyn RE, Withers HR (eds) Radiation biology in cancer research. Raven, New York, pp 241–262 Bedford JS, Mitchell JB, Fox M (1980) Variations in responses of several mammalian cell lines to low dose-rate irradiation. In: Meyn RE, Withers HR (eds) Radiation biology in cancer research. Raven, New York, pp 241–262
go back to reference Blagosklonny MV, Pardee AB (2001) Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61:4301–4305PubMed Blagosklonny MV, Pardee AB (2001) Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61:4301–4305PubMed
go back to reference Bohm (2000) Influence of pentoxyfilline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Biochim Biophys Acta 1499:1–10CrossRefPubMed Bohm (2000) Influence of pentoxyfilline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Biochim Biophys Acta 1499:1–10CrossRefPubMed
go back to reference Deweese TL, Shipman JM, Dillehay LE, Nelson WG (1998) Sensitivity of human prostatic carcinoma cell lines to low-dose rate radiation exposure. J Urol 159:591–598PubMed Deweese TL, Shipman JM, Dillehay LE, Nelson WG (1998) Sensitivity of human prostatic carcinoma cell lines to low-dose rate radiation exposure. J Urol 159:591–598PubMed
go back to reference Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672PubMed Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672PubMed
go back to reference Formenti SC, Symmans WF, Volm M, Skinner K, Cohen D, Spicer D, Danenberg PV (1999) Concurrent paclitaxel and radiationtherapy for breast cancer. Sem Rad Oncol 9:34–42 Formenti SC, Symmans WF, Volm M, Skinner K, Cohen D, Spicer D, Danenberg PV (1999) Concurrent paclitaxel and radiationtherapy for breast cancer. Sem Rad Oncol 9:34–42
go back to reference Fowler JF (1990) Radiobiological aspects of low-dose rate in radioimmunotherapy. Int J Rad Oncol Biol Phys 18:1261–1269 Fowler JF (1990) Radiobiological aspects of low-dose rate in radioimmunotherapy. Int J Rad Oncol Biol Phys 18:1261–1269
go back to reference Geldof AA, Rooij L de, Versteegh RT, Newling DWW, Teule GJJ (1999a) Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med 40:667–671PubMed Geldof AA, Rooij L de, Versteegh RT, Newling DWW, Teule GJJ (1999a) Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med 40:667–671PubMed
go back to reference Geldof AA, Kruit A, Newling DWW, Slotman BJ (1999b) Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line. Anticancer Res 19:505–508PubMed Geldof AA, Kruit A, Newling DWW, Slotman BJ (1999b) Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line. Anticancer Res 19:505–508PubMed
go back to reference Griffith TD, Tolmach LJ (1976) Lethal response of HeLa cells to X-irradiation in the latter part of the generation cycle. Biophys J 16:303–318PubMed Griffith TD, Tolmach LJ (1976) Lethal response of HeLa cells to X-irradiation in the latter part of the generation cycle. Biophys J 16:303–318PubMed
go back to reference Gupta N, Hu LJ, Deen DF (1997) Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Rad Oncol Biol Phys 37:885–895CrossRef Gupta N, Hu LJ, Deen DF (1997) Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Rad Oncol Biol Phys 37:885–895CrossRef
go back to reference Hall EJ (1994) Radiosensitivity and cell age in the mitotic cycle. In: Hall EJ (ed) Radiobiology for the radiologist, 4th ed. Lippincott, Philadelphia, pp 91–105 Hall EJ (1994) Radiosensitivity and cell age in the mitotic cycle. In: Hall EJ (ed) Radiobiology for the radiologist, 4th ed. Lippincott, Philadelphia, pp 91–105
go back to reference Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 226:1821–1828 Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 226:1821–1828
go back to reference Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20Bcells. Cancer Res 56:1842–1850PubMed Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20Bcells. Cancer Res 56:1842–1850PubMed
go back to reference Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM (1999) p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 96:2147–2152 Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM (1999) p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 96:2147–2152
go back to reference Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716–4720PubMed Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716–4720PubMed
go back to reference Kal HB, Barendsen GW, Bakker-van Haue R, Roeke H (1975) Increased radiosensitivity of rat rhabdomyosarcoma cells induced by protracted irradiation. Rad Res 63:521–530 Kal HB, Barendsen GW, Bakker-van Haue R, Roeke H (1975) Increased radiosensitivity of rat rhabdomyosarcoma cells induced by protracted irradiation. Rad Res 63:521–530
go back to reference Kano Y, Akutsu M, Tsunoda S, Furata M, Yazawa Y, Ando J (1998) Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines. Oncol Res 10:347–354PubMed Kano Y, Akutsu M, Tsunoda S, Furata M, Yazawa Y, Ando J (1998) Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines. Oncol Res 10:347–354PubMed
go back to reference Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed
go back to reference Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK (2000) The in vivo effect of Bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry and blood flow. Clin Cancer Res 6:1498–1507PubMed Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK (2000) The in vivo effect of Bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry and blood flow. Clin Cancer Res 6:1498–1507PubMed
go back to reference Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491–7495 Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491–7495
go back to reference Lundberg AS, Weinberg RA (1999) Control of the cell cycle and apoptosis. Europ J Cancer 35:531–539CrossRef Lundberg AS, Weinberg RA (1999) Control of the cell cycle and apoptosis. Europ J Cancer 35:531–539CrossRef
go back to reference Mastbergen SC, Duivenvoorden I, Versteegh RT, Geldof AA (2000) Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs. Anticancer Res 20:1833–1838PubMed Mastbergen SC, Duivenvoorden I, Versteegh RT, Geldof AA (2000) Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs. Anticancer Res 20:1833–1838PubMed
go back to reference Mitchell JB, Bedford JS, Bailey SM (1979) Dose-rate effects in mammalian cells in culture III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Rad Res 79:537–551 Mitchell JB, Bedford JS, Bailey SM (1979) Dose-rate effects in mammalian cells in culture III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Rad Res 79:537–551
go back to reference Russell KJ, Wiens LW, Demers GW, Galloway DA, Le T, Rice GC, Bianco JA, Singer JW, Groudine M (1996) Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Rad Oncol Biol Phys 36:1099–1106CrossRef Russell KJ, Wiens LW, Demers GW, Galloway DA, Le T, Rice GC, Bianco JA, Singer JW, Groudine M (1996) Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Rad Oncol Biol Phys 36:1099–1106CrossRef
go back to reference Schiff PB, Fant J, Horowitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22:665–667 Schiff PB, Fant J, Horowitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22:665–667
go back to reference Schiff PB, Horowitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565PubMed Schiff PB, Horowitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565PubMed
go back to reference Sinclair WK (1968) Cyclic X-ray responses in mammalian cells in vitro. Rad Res 33:620–643 Sinclair WK (1968) Cyclic X-ray responses in mammalian cells in vitro. Rad Res 33:620–643
go back to reference Van Buul PPW, van Duyn-Goedhart A, Beumers T, Bootsma AL (2001) Role of cell cycle control in radiosensitization of mouse spermatogonial stem cells. Int J Radiat Biol 77:357–363CrossRefPubMed Van Buul PPW, van Duyn-Goedhart A, Beumers T, Bootsma AL (2001) Role of cell cycle control in radiosensitization of mouse spermatogonial stem cells. Int J Radiat Biol 77:357–363CrossRefPubMed
go back to reference Van Leeuwen-Stok EA, Jonkhoff AR, Visser-Platier AW, Drager LM, Teule GJ, Huijgens PC, Schuurhuis GJ (1998) Cell cycle dependency of 67gallium uptake and cytotoxicity in human cell lines of hematological malignancies. Leuk Lymph 31:533–544PubMed Van Leeuwen-Stok EA, Jonkhoff AR, Visser-Platier AW, Drager LM, Teule GJ, Huijgens PC, Schuurhuis GJ (1998) Cell cycle dependency of 67gallium uptake and cytotoxicity in human cell lines of hematological malignancies. Leuk Lymph 31:533–544PubMed
go back to reference Wang S, Guo CY, Castillo A, Dent P, Grant S (1998) Effect of Bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 56:635–644CrossRefPubMed Wang S, Guo CY, Castillo A, Dent P, Grant S (1998) Effect of Bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 56:635–644CrossRefPubMed
go back to reference Wang XW, Zhan Q, Coursen JD, Khan MA, Ktny U, Yu L, Hollander MC, O'connor PM, Fornace AJ, Harris CC (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706–3711CrossRefPubMed Wang XW, Zhan Q, Coursen JD, Khan MA, Ktny U, Yu L, Hollander MC, O'connor PM, Fornace AJ, Harris CC (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706–3711CrossRefPubMed
go back to reference Zoli W, Ricotto L, Barzanti F, Dal Susino M, Frassineti GL, Miland C, Casadei Giunchi D, Amadori D (1999) Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80: 413–416CrossRefPubMed Zoli W, Ricotto L, Barzanti F, Dal Susino M, Frassineti GL, Miland C, Casadei Giunchi D, Amadori D (1999) Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80: 413–416CrossRefPubMed
Metadata
Title
Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line
Authors
Albert A. Geldof
Marian A.B.D. Plaizier
Ilse Duivenvoorden
Marieke Ringelberg
Richard T. Versteegh
Don W.W. Newling
Gerrit J.J. Teule
Publication date
01-03-2003
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2003
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-002-0412-8

Other articles of this Issue 3/2003

Journal of Cancer Research and Clinical Oncology 3/2003 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.